Fairvalue-Calculator Fairvalue-Calculator
EN DE

Epitomee Medical Ltd (EPIT) Fair Value & Analysis

Healthcare · Il · Market cap 207M ILA

Price6.56 ILA
Fair Value12.35 ILA
Upside+88.2%
Quality95/100
Evidence: Low Range 9.26 ILA – 15.43 ILA

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Epitomee Medical Ltd (EPIT) currently trades at 6.56 ILA, while our model-based Fair Value estimate is 12.35 ILA — implying the stock looks roughly 88.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Epitomee Medical Ltd develops and commercializes ingestible therapeutic devices in Israel. The company offers capsules for the treatment of overweight and obesity. It also focuses on developing biologic drug delivery solutions. Epitomee Medical Ltd was incorporated in 2005 and is based in Caesarea, Israel.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +19%

Frequently asked questions

Is Epitomee Medical Ltd (EPIT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 12.35 ILA versus a price of 6.56 ILA — about +88% (undervalued). Model-based estimate, not financial advice.
What is the fair value of EPIT?
Our 21-model fair value for Epitomee Medical Ltd is 12.35 ILA (as of Jun 24, 2026), built from audited fundamentals. The current price is 6.56 ILA.
What is the quality score of EPIT?
Epitomee Medical Ltd has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.